Abstract 88P
Background
PPM1D/WIP1 is a Ser/Thr phosphatase activated upon genotoxic stress in a p53 dependent manner and involved in regulation of DNA damage response (DDR) . Wip1 is amplified and over expressed in common human cancers and thus exerts oncogenic functions. Oncogenic Wip1 negatively regulates cellular responses to chemotherpy such as apoptosis and senescence. Here, we aimed to investigate the role of oncogenic Wip1 in induction of basal autophagy and chemotherpy mediated autophagy in breast cancer cells.
Methods
Etoposide was used to induce autophagy and Chloroquin (CQ) for inhibition. GSK2830371 was used to inhibit Wip1. LC3I/II conversion P62 degradation, total and phosphorylated (Ulk1 p-Ser757) levels were by analysed WB. Wip1-Ulk1 interaction was demonstrated by co-IP analysis. LC3 puncta formation was analysed by and immunofluorescence staining. Apoptosis, cell cycle, and senescence were measured by AnnexinV/7AAD, BrdU/PI analysis and SAβ-gal staining, respectively Colony formation assay was used to assess cells ability to colonize.
Results
Utilizing Wip1 over expressing MCF-7 cells, here we showed that oncogenic Wip1 increased basal autophagy and mediated etoposide-induced autophagy as confirmed by accumulation of LC3-II, degradation of p62, and formation of LC3II puncta. Inhibition of Wip1 increased phosphorylation of Ulk1 from Ser757 both in basal and etoposide induced autophagy. Further, endogenous Wip1 co-precipitated with Wip1 during basal and etoposide induced autophagy. Inhibition of autophagy or Wip1 enhanced apoptosis in response to etoposide but not senescence.
Conclusions
In conclusion our data suggest that oncogenic Wip1 may increase basal autophagy to support the survival of cancer cells. In addition Wip1 dependent autophagy in response to chemotherpy agents may cause resistance to chemotherapy. Thus targeting of Wip1-Ulk1 may lead enhancement of the chemotherapy response as a promising therapetic strategy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M.K. Kilic Eren.
Funding
This work is supported by TUBITAK Gr.N . 119S135.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35P - SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Presenter: Sukanya Patra
Session: Poster session 09
36P - Molecular assessment of clinical antitumour therapeutics utilising established pancreatic ductal adenocarcinoma patient-derived models
Presenter: Young-Ah Suh
Session: Poster session 09
37P - Nischarin can be a target for stromal normalisation in pancreatic ductal adenocarcinoma
Presenter: Jelena Grahovac
Session: Poster session 09
38P - Effects of antiemetics on zolbetuximab-induced gastric injury and emesis frequency in ferrets
Presenter: Jane Weng
Session: Poster session 09
39P - Casein kinase 2 modulates epithelial–mesenchymal transition through helicobacter pylori CagA-dependent pathway in gastric cancer cells
Presenter: SODAM LEE
Session: Poster session 09
40P - Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2
Presenter: Irene Moreno
Session: Poster session 09
42P - Developing a photodynamic therapy strategy targeted to endometrial cancer stem cells
Presenter: Beatriz Serambeque
Session: Poster session 09
43P - Looking for therapeutic targets on the proteome profile of endometrial cancer stem cells
Presenter: Mafalda Laranjo
Session: Poster session 09
44P - PAUF as a target for treatment of high PAUF-expressing ovarian cancer
Presenter: Junghyun Cho
Session: Poster session 09